COVID-19: Abnormal liver function tests

被引:691
作者
Cai, Qingxian [1 ]
Huang, Deliang [1 ]
Yu, Hong [1 ]
Zhu, Zhibin [1 ]
Xia, Zhang [1 ]
Su, Yinan [1 ]
Li, Zhiwei [1 ]
Zhou, Guangde [1 ]
Gou, Jizhou [1 ]
Qu, Jiuxin [1 ]
Sun, Yan [1 ]
Liu, Yingxia [1 ]
He, Qing [1 ]
Chen, Jun [1 ]
Liu, Lei [1 ]
Xu, Lin [2 ]
机构
[1] Southern Univ Sci & Technol, Natl Clin Res Ctr Infect Dis, Peoples Hosp Shenzhen 3, Affiliated Hosp 2, Shenzhen 518100, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou, Guangdong, Peoples R China
关键词
2019-nCoV; SARS-Cov-2; Pneumonia; Critical care; Liver injury; Liver tests; Bilirubin; PNEUMONIA;
D O I
10.1016/j.jhep.2020.04.006
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Recent data on the coronavirus disease 2019 (COVID-19) outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has begun to shine light on the impact of the disease on the liver. But no studies to date have systematically described liver test abnormalities in patients with COVID-19. We evaluated the clinical characteristics of COVID-19 in patients with abnormal liver test results. Methods: Clinical records and laboratory results were obtained from 417 patients with laboratory-confirmed COVID-19 who were admitted to the only referral hospital in Shenzhen, China from January 11 to February 21, 2020 and followed up to March 7, 2020. Information on clinical features of patients with abnormal liver tests were collected for analysis. Results: Of 417 patients with COVID-19, 318 (76.3%) had abnormal liver test results and 90 (21.5%) had liver injury during hospitalization. The presence of abnormal liver tests became more pronounced during hospitalization within 2 weeks, with 49 (23.4%), 31 (14.8%), 24 (11.5%) and 51 (24.4%) patients having alanine aminotransferase, aspartate aminotransferase, total bilirubin and gamma-glutamyl transferase levels elevated to more than 3x the upper limit of normal, respectively. Patients with abnormal liver tests of hepatocellular type or mixed type at admission had higher odds of progressing to severe disease (odds ratios [ORs] 2.73; 95% CI 1.19-6.3, and 4.44, 95% CI 1.93-10.23, respectively). The use of lopinavir/ritonavir was also found to lead to increased odds of liver injury (OR from 4.44 to 5.03, both p <0.01). Conclusion: Patients with abnormal liver tests were at higher risk of progressing to severe disease. The detrimental effects on liver injury mainly related to certain medications used during hospitalization, which should be monitored and evaluated frequently. Lay summary: Data on liver tests in patients with COVID-19 are scarce. We observed a high prevalence of liver test abnormalities and liver injury in 417 patients with COVID-19 admitted to our referral center, and the prevalence increased substantially during hospitalization. The presence of abnormal liver tests and liver injury were associated with the progression to severe pneumonia. The detrimental effects on liver injury were related to certain medications used during hospitalization, which warrants frequent monitoring and evaluation for these patients. (C) 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:566 / 574
页数:9
相关论文
共 33 条
  • [1] EASL Clinical Practice Guidelines: Drug-induced liver injury
    Andrade, Raul J.
    Aithal, Guruprasad P.
    Bjornsson, Einar S.
    Kaplowitz, Neil
    Kullak-Ublick, Gerd A.
    Karlsen, Tom H.
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (06) : 1222 - 1261
  • [2] Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance
    不详
    [J]. PEDIATRIA I MEDYCYNA RODZINNA-PAEDIATRICS AND FAMILY MEDICINE, 2020, 16 (01): : 9 - 26
  • [3] Presumed Asymptomatic Carrier Transmission of COVID-19
    Bai, Yan
    Yao, Lingsheng
    Wei, Tao
    Tian, Fei
    Jin, Dong-Yan
    Chen, Lijuan
    Wang, Meiyun
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (14): : 1406 - 1407
  • [4] Chai X, 2020, bioRxiv, DOI [10.1101/2020.02.03.931766, 10.1101/2020.02.03.931766, DOI 10.1101/2020.02.03.931766]
  • [5] SARS-associated viral hepatitis caused by a novel coronavirus: Report of three cases
    Chau, TN
    Lee, KC
    Yao, H
    Tsang, TY
    Chow, TC
    Yeung, YC
    Choi, KW
    Tso, YK
    Lau, T
    Lai, ST
    Lai, CL
    [J]. HEPATOLOGY, 2004, 39 (02) : 302 - 310
  • [6] Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
    Chen, Nanshan
    Zhou, Min
    Dong, Xuan
    Qu, Jieming
    Gong, Fengyun
    Han, Yang
    Qiu, Yang
    Wang, Jingli
    Liu, Ying
    Wei, Yuan
    Xia, Jia'an
    Yu, Ting
    Zhang, Xinxin
    Zhang, Li
    [J]. LANCET, 2020, 395 (10223) : 507 - 513
  • [7] Angiotensin-Converting Enzyme 2: The First Decade
    Clarke, Nicola E.
    Turner, Anthony J.
    [J]. INTERNATIONAL JOURNAL OF HYPERTENSION, 2012, 2012
  • [8] Dillon JF, 2016, GAMMA GLUTAMYL TRANS
  • [9] Dong Yukang, 2019, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V31, P571, DOI 10.3760/cma.j.issn.2095-4352.2019.05.010
  • [10] EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
    Marchesini G.
    Day C.P.
    Dufour J.-F.
    Canbay A.
    Nobili V.
    Ratziu V.
    Tilg H.
    Roden M.
    Gastaldelli A.
    Yki-Järvinen H.
    Schick F.
    Vettor R.
    Frühbeck G.
    Mathus-Vliegen L.
    [J]. OBESITY FACTS, 2016, 9 (02) : 65 - 90